(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations. Read More
(Correcting day of the week in the opening sentence.) Read More
(Alliance News) - Stock prices in London closed lower on Thursday, with the FTSE 100's recent rally taking a pause for breath, but not after hitting another record high. Read More
(Alliance News) - Angle PLC shares rose on Wednesday, after it signed a contract with AstraZeneca PLC. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday. Read More
Angle PLC - Surrey-based medical diagnostics provider - Says it has been granted a European and US patent for its CellKeep slide. "We are delighted to have secured intellectual property rights for our proprietary CellKeep slide in two major jurisdictions....This is a significant technology advancement for the [circulating tumor cell] liquid biopsy field and another step towards enabling biomarker-guided precision medicine for people with cancer," says Chief Executive Officer Andrew Newland. The CellKeep slide was developed by Angle to reduce cell loss during the transfer of CTCs to the microscope slide and to protect the morphology of the harvested cells. Read More
Angle PLC - Surrey-based medical diagnostics provider - Announces publication of a peer-reviewed paper in a special issue of the journal - "Current Issues in Molecular Biology" Special Issue: Advanced Solutions for Cancer Therapy. Article brings together supporting evidence for the additional and complementary information that can be obtained from circulating tumour cells, demonstrating the value of a dual analyte approach for both CTCs and ctDNA (fragments of DNA released mainly by dying cells). Angle recently announced breakthrough data for real-time parallel next generation sequencing DNA analysis of both ctDNA and CTCs from a single tube of patient blood, using a pan-cancer panel run on an Illumina NGS system. Read More
(Alliance News) - Stock prices in London closed higher on Thursday, as investors eye the latest US non-farms data. Read More
(Alliance News) - Angle PLC on Thursday said that "breakthrough results" from its latest blood sample cancer trials would allow it to expand its product sales and pharma services. Read More
(Alliance News) - Stock prices in London were slightly higher at midday on Thursday, with the FTSE 100 looking set to snap the two-day losing streak it suffered at the start of the year. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday. Read More
(Alliance News) - Stock prices in London opened up on Thursday, amid a slew of services PMI data, including for the UK, while reacting to the latest data from China. Read More
(Alliance News) - Angle PLC has hit a "landmark achievement", says Berenberg, as its pilot study partnership with Eisai Inc may lead to major market expansion. Read More
Angle PLC - Surrey, England-based medical diagnostics - Signs contract with Eisai Inc, part of Tokyo-based pharmaceutical firm Eisai Co Ltd. Under the agreement, the two will engage in a pilot study worth USD250,000 to Angle. Angle will provide circulating-tumour-cells analysis using its Portrait HER2 assay to assess the response of breast cancer patients to Eisai's BB-1701 antibody-drug conjugate. BB-1701 targets HER2, a protein that speeds up the growth of breast cancer cells. Success in the phase two pilot study will offer the possibility for multiple follow-up studies. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
Angle PLC - Surrey, England-based medical diagnostics company - Launches its Portrait Plus CTC staining kit at the San Antonio Breast Cancer Symposium, following "extensive" development, optimisation and validation of the kit. Explains that the kit is read-to-use, and designed for the dentification, characterisation and enumeration of epithelial and mesenchymal cancer cells. This includes those undergoing epithelial-to-mesenchymal transition. Read More
(Alliance News) - Angle PLC on Thursday said it expects revenue in 2023 to more than double from 2022 as it announced the launch of a new test aimed to support cancer therapy studies. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - Angle PLC on Tuesday touted the publication of a study by researchers at the University of Tubingen in Germany, which showed that its Parsortix system outperformed the current laboratory standard for disseminated tumour cell harvest. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning: Read More